270 related articles for article (PubMed ID: 32890663)
1. Discovery of HIV entry inhibitors via a hybrid CXCR4 and CCR5 receptor pharmacophore-based virtual screening approach.
Mirza MU; Saadabadi A; Vanmeert M; Salo-Ahen OMH; Abdullah I; Claes S; De Jonghe S; Schols D; Ahmad S; Froeyen M
Eur J Pharm Sci; 2020 Dec; 155():105537. PubMed ID: 32890663
[TBL] [Abstract][Full Text] [Related]
2. Comparison of ligand-based and receptor-based virtual screening of HIV entry inhibitors for the CXCR4 and CCR5 receptors using 3D ligand shape matching and ligand-receptor docking.
Pérez-Nueno VI; Ritchie DW; Rabal O; Pascual R; Borrell JI; Teixidó J
J Chem Inf Model; 2008 Mar; 48(3):509-33. PubMed ID: 18298095
[TBL] [Abstract][Full Text] [Related]
3. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
[TBL] [Abstract][Full Text] [Related]
4. Function-oriented development of CXCR4 antagonists as selective human immunodeficiency virus (HIV)-1 entry inhibitors.
Wu CH; Wang CJ; Chang CP; Cheng YC; Song JS; Jan JJ; Chou MC; Ke YY; Ma J; Wong YC; Hsieh TC; Tien YC; Gullen EA; Lo CF; Cheng CY; Liu YW; Sadani AA; Tsai CH; Hsieh HP; Tsou LK; Shia KS
J Med Chem; 2015 Feb; 58(3):1452-65. PubMed ID: 25584630
[TBL] [Abstract][Full Text] [Related]
5. HIV co-receptors as targets for antiviral therapy.
Schols D
Curr Top Med Chem; 2004; 4(9):883-93. PubMed ID: 15134547
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists.
De Clercq E; Schols D
Antivir Chem Chemother; 2001; 12 Suppl 1():19-31. PubMed ID: 11594685
[TBL] [Abstract][Full Text] [Related]
7. Design and computational support for the binding stability of a new CCR5/CXCR4 dual tropic inhibitor: Computational design of a CCR5/CXCR4 drug.
Taylor CA; Miller BR; Parish CA
J Mol Graph Model; 2017 Aug; 75():71-79. PubMed ID: 28575798
[TBL] [Abstract][Full Text] [Related]
8. Pharmacophore-Oriented Identification of Potential Leads as CCR5 Inhibitors to Block HIV Cellular Entry.
Singh P; Kumar V; Lee G; Jung TS; Ha MW; Hong JC; Lee KW
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555761
[TBL] [Abstract][Full Text] [Related]
9. Integrated computational tools for identification of CCR5 antagonists as potential HIV-1 entry inhibitors: homology modeling, virtual screening, molecular dynamics simulations and 3D QSAR analysis.
Moonsamy S; Dash RC; Soliman ME
Molecules; 2014 Apr; 19(4):5243-65. PubMed ID: 24762964
[TBL] [Abstract][Full Text] [Related]
10. Targeting CXCR4 in HIV cell-entry inhibition.
Steen A; Schwartz TW; Rosenkilde MM
Mini Rev Med Chem; 2009 Dec; 9(14):1605-21. PubMed ID: 20088780
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of R5X4 dualtropic HIV-1 primary isolates by single chemokine co-receptor ligands.
Ghezzi S; Menzo S; Brambilla A; Bordignon PP; Lorini AL; Clementi M; Poli G; Vicenzi E
Virology; 2001 Feb; 280(2):253-61. PubMed ID: 11162839
[TBL] [Abstract][Full Text] [Related]
12. Penicillixanthone A, a marine-derived dual-coreceptor antagonist as anti-HIV-1 agent.
Tan S; Yang B; Liu J; Xun T; Liu Y; Zhou X
Nat Prod Res; 2019 May; 33(10):1467-1471. PubMed ID: 29258357
[TBL] [Abstract][Full Text] [Related]
13. Development of anti-HIV agents targeting dynamic supramolecular mechanism: entry and fusion inhibitors based on CXCR4/CCR5 antagonists and gp41-C34-remodeling peptides.
Tamamura H; Otaka A; Fujii N
Curr HIV Res; 2005 Oct; 3(4):289-301. PubMed ID: 16250877
[TBL] [Abstract][Full Text] [Related]
14. Co-receptor antagonists as HIV-1 entry inhibitors.
Shaheen F; Collman RG
Curr Opin Infect Dis; 2004 Feb; 17(1):7-16. PubMed ID: 15090884
[TBL] [Abstract][Full Text] [Related]
15. Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs.
Seibert C; Sakmar TP
Curr Pharm Des; 2004; 10(17):2041-62. PubMed ID: 15279544
[TBL] [Abstract][Full Text] [Related]
16. Role of CXCR4 in cell-cell fusion and infection of monocyte-derived macrophages by primary human immunodeficiency virus type 1 (HIV-1) strains: two distinct mechanisms of HIV-1 dual tropism.
Yi Y; Isaacs SN; Williams DA; Frank I; Schols D; De Clercq E; Kolson DL; Collman RG
J Virol; 1999 Sep; 73(9):7117-25. PubMed ID: 10438797
[TBL] [Abstract][Full Text] [Related]
17. Different Patterns of HIV-1 Replication in MACROPHAGES is Led by Co-Receptor Usage.
Borrajo A; Ranazzi A; Pollicita M; Bellocchi MC; Salpini R; Mauro MV; Ceccherini-Silberstein F; Perno CF; Svicher V; Aquaro S
Medicina (Kaunas); 2019 Jun; 55(6):. PubMed ID: 31234437
[No Abstract] [Full Text] [Related]
18. CCR5/CXCR4 Dual Antagonism for the Improvement of HIV Infection Therapy.
Grande F; Occhiuzzi MA; Rizzuti B; Ioele G; De Luca M; Tucci P; Svicher V; Aquaro S; Garofalo A
Molecules; 2019 Feb; 24(3):. PubMed ID: 30717348
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel HIV entry inhibitors for the CXCR4 receptor by prospective virtual screening.
Pérez-Nueno VI; Pettersson S; Ritchie DW; Borrell JI; Teixidó J
J Chem Inf Model; 2009 Apr; 49(4):810-23. PubMed ID: 19358515
[TBL] [Abstract][Full Text] [Related]
20. Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.
Panos G; Watson DC
Crit Rev Microbiol; 2015; 41(4):473-87. PubMed ID: 24635642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
